Spotlight Series on Hepatitis C


Affordable Hepatitis C Medicine Can Cut Number of New Infections

July 28, 2014

Financial Times: Global push can bring remedies within reach of all who need them
Stefan Wiktor, team leader of the WHO's global hepatitis program, and Gottfried Hirnschall, director of WHO's HIV department

"We are witnessing a remarkable transformation in the treatment of hepatitis C virus infection (HCV). Intensive research is beginning to yield a number of new 'direct-acting antiviral' medicines that have shortened and simplified treatment of HCV and produced high cure rates. This offers a real possibility that we can dramatically reduce the numbers of people who die each year from liver cancer and cirrhosis because of HCV infection. ... An estimated 500,000-700,000 people die each year from liver cancer and cirrhosis caused by HCV. The new treatments provide a remarkable opportunity to cut the number significantly and prevent new infections. This can only be realized if there is a global effort to make the medicines affordable and to invest in health care services in order that the medicines can reach those who need them" (7/27).

Back to other news for July 2014

This information was reprinted from with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.